The potential of miR-499 plasmatic level as a biomarker of obstructive sleep apnea syndrome.
David SloukaJindra WindrichovaHana ŘezáčkováKaterina HoufkovaRadek KučeraVaclava CernaTomáš KostlivýOndrej TopolcanMartin PestaPublished in: Biomarkers in medicine (2021)
Background: Obstructive sleep apnea syndrome (OSAS) is one of the most common sleep-related breathing disorders. The aim of this study was to improve diagnostics in OSAS using blood circulating biomarkers. We consider the potential of cardiac-specific miRNAs in the diagnosis and risk assessment of cardiovascular complications. Materials & methods: Plasmatic levels of miR-1-3p, miR-133a-3p and miR-499a-5p were measured by reverse transcription-PCR and compared with the clinical status of OSAS patients and controls. Results: The level of miR-499 was higher (p = 0.0343) in OSAS patients (mean expression: 0.00561) compared with the controls (mean expression: 0.00003), using the multivariate logistic regression. Conclusion: The role of miR-499 in gene expression regulation during hypoxia and our findings indicate that miR-499 could be a new diagnostic biomarker for OSAS.
Keyphrases
- obstructive sleep apnea
- long non coding rna
- cell proliferation
- gene expression
- risk assessment
- end stage renal disease
- poor prognosis
- ejection fraction
- newly diagnosed
- long noncoding rna
- chronic kidney disease
- prognostic factors
- transcription factor
- left ventricular
- dna methylation
- positive airway pressure
- patient reported